We believe great partnerships create great possibilities and are inspired by our partners
As a global biopharmaceutical company, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
Exclusively sourcing our pipeline through external innovation, we have no internal competing pipeline as we recognize the best science is delivered in biotech and academic institutions. We are proud our team comprises talents attracted from Pharma, biotech and academia, to drive shared success through creative collaborations.
ONCOLOGY
Where we plan to expand
Solid tumors & hematology
- Precision medicine approaches
- BIC/FIC with strong science and meaningful differentiation
Smaller patient segments attractive for mid-sized companies
RARE DISEASE
Where we plan to expand
High unmet needs in underserved rare diseases
Drive liver & bone franchises; expand to new disease areas
Good fit for clinical development & go-to-market model
NEUROSCIENCE
Where we plan to expand
Rare neuroscience
Expand beyond neurotoxins in non-rare to adjacent areas
Strong innovation & scientific advances
Partnering with Ipsen
As a mid-size pharma, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
At Ipsen, we believe great partnerships create great possibilities. Data is just the beginning; we go beyond this to translate the clinical benefit into true patient impact. We focus on how one patient will have an enhanced experience because of each innovation and unite expertise to deliver this.
Pipeline
Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across Oncology, Rare Disease and Neuroscience.
Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases
PARIS, FRANCE, 17 May 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from its growing rare disease portfolio will be presented at the 55th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN),…
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
PARIS, FRANCE, 3 March 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s Rare Disease portfolio, with…
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
PARIS, FRANCE & BOSTON, U.S., 09 January 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators…
Ipsen to acquire Epizyme, expanding its portfolio in oncology
PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 27 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by…
Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.
April 9, 2019 at 12:29 PM EDT
Q1 2024 sales update
The Q1 2024 sales announcement will be published on April 24, 2024 at 7am CET. Find out more and register for the conference call for investors and analysts.
Applications now open for the 2024 Golden Ticket competition
As part of our commitment to accelerating transformative research and development, we’re excited to announce that our annual Golden Ticket competition is now open! Through our continued partnership with BioLabs, we’re delighted to be offering the brightest minds in biotech…
FY 2023 results announcement
Ipsen’s FY 2023 results announcement took place on 8 February 2024 at 7am CET/1am EST.
Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics
Starting now and throughout 2024, Ipsen is sponsoring five talented, elite athletes on their journeys toward the 2024 Paralympic Games.
Examining the European Pharma legislation: EFPIA publishes the Dolon Report
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation…
Capital Markets Day 2023
Ipsen plans to host a capital-markets day, starting at 12.30 pm GMT on 7 December 2023, at The Brewery, London. In-person attendance is by invitation only.
2023 year to date and third-quarter sales results
Ipsen has published its year to date and third-quarter sales results on 26 October 2023 at 7am CET.
Winner of Ipsen’s golden ticket announced as newest resident of Biolabs Hôtel Dieu
We are pleased to announce that Hemerion has been awarded Ipsen’s golden ticket 2023, receiving a year’s free lab space at the brand new, cutting-edge facility in the heart of Paris, France, close to Notre-Dame, at Paris Hôpital Hotel Dieu, AP-HP.
David Loew, Philippe Lopes Fernandes inaugurate Biolabs – Hôtel Dieu
Biolabs, a new biotech incubator located in the historic Hôtel Dieu, was inaugurated on 6 July 2023. As a founding sponsor of the initiative, Ipsen was represented at the event by CEO David Loew and Chief Business Officer Philippe Lopes…
Ipsen’s 2022 Integrated Annual Report now available
2022 was a year of focus, momentum and growth at Ipsen. Learn about the progress we made and download the 2022 Integrated Annual Report here.